ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma.

Zinzani, P.L.; Mayer J.; Flowers C.R.; Bijou F.; De Oliveira A.C.; Song Y.; Zhang Q.; Merli M.; Bouabdallah K.; Ganly P.; Zhang H.; Johnson R.; Martin Garcia-Sancho A.; Provencio Pulla M.; Trneny M.; Yuen S.; Tilly H.; Kingsley E.; Tumyan G.; Assouline S.E.; Auer R.; Ivanova E.; Kim P.; Huang S.; Delarue R.; Trotman J.

ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma.

All Authors

Zinzani, P.L.

Mayer J.

Flowers C.R.

Bijou F.

De Oliveira A.C.

Song Y.

Zhang Q.

Merli M.

Bouabdallah K.

Ganly P.

Show 10 more

LTHT Author

Johnson, Rod

LTHT Department

Haematology

Publication Date

2023

Item Type

Conference Paper

Abstract

PURPOSEThe combination of zanubrutinib plus obinutuzumab (ZO) was found to be well tolerated with an early signal of efficacy in a phase Ib study. ROSEWOOD is a phase II, randomized study that assessed the efficacy and safety of ZO versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).METHODSPatients with R/R FL who had received a 2 lines of therapy, including an anti-CD20 antibody and an alkylating agent, were randomly assigned 2:1 to receive ZO or obinutuzumab (O). The primary end point was overall response rate (ORR) by independent central review (ICR). Secondary end points included duration of response (DOR), progression-free survival (PFS), overall survival, and safety.RESULTSA total of 217 patients were randomized (ZO, 145; O, 72). Median study follow-up was 20.2 months. The study met its primary end point: ORR by ICR was 69% (ZO) versus 46% (O; P =.001). Complete response rate was 39% (ZO) versus 19% (O); 18-month DOR rate was 69% (ZO) versus 42% (O). Median PFS was 28.0 months (ZO) versus 10.4 months (O; hazard ratio, 0.50 [95% CI, 0.33 to 0.75]; P <.001). The most common adverse events with ZO were thrombocytopenia, neutropenia, diarrhea, and fatigue; incidences of atrial fibrillation and major hemorrhage were 3% and 1%, respectively.CONCLUSIONThe combination of ZO met its primary end point of a superior ORR versus O, and demonstrated meaningful activity and a manageable safety profile in patients with R/R FL. ZO had a favorable benefit-risk profile compared with O, and represents a potential combination therapy for patients with R/R FL.